The Administration is using Section 232 in a new way, and it's not merely just to raise duties, but to reshape pharmaceutical sourcing, pricing and manufacturing strategy. A new proclamation imposes a default 100% tariff on patented pharmaceuticals, APIs and key starting materials, effective beginning July 31 and September 29, 2026. With enforcement and audits expected, companies should treat this as the start of a broader compliance and restructuring cycle. Deanna Okun, Lydia Pardini, Dominic Bianchi and Jane C. Dempsey break down what to know and what to do next: https://lnkd.in/gFyKa_Xe.
US Administration Imposes 100% Tariff on Patented Pharmaceuticals
This title was summarized by AI from the post below.
